Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese major depression drug market will triple by 2012, growing from $75 million in 2007 to $226 million in 2012. Selective serotonin reuptake inhibitors (SSRIs), the market-leading drug class, will continue to experience strong double-digit growth, contributing to the annual 20 percent growth of the major depression drug market during the forecast period.

According to the new Emerging Markets report entitled Major Depression in China, this growth will be fueled in part by increasing urbanization and a greater exposure to risk factors.

"The risk of major depression among urban populations is more than four times that of rural populations. Major depression is most common in urban areas of China with over 75 percent of prevalent cases found in these areas in 2007," stated Matthew Winton, Ph.D., analyst at Decision Resources.

The report also finds that Chinese physicians and patients prefer Western medicines to Chinese-manufactured products. Although Chinese physicians generally regard Western-manufactured antidepressants as being of much higher quality than locally manufactured drugs, many Chinese-manufactured drugs have achieved a majority of the market share, largely due to their lower prices.

"Western drug companies should consider competitive pricing of their branded drugs, relative to their Western competitors, as part of their strategic entry into China. Strategic pricing could offer multinational companies a distinct competitive advantage in this rapidly growing market," added Dr. Winton.

  EMERGING MARKETS REPORTS   The Ultimate Analysis of Pharmaceutical Markets in China and India 

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Natalia Morales                       Elizabeth Marshall   Decision Resources                    Decision Resources, Inc.   781-296-2691                          781-296-2563      

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,; Elizabeth Marshall of Decision Resources, Inc.,

Gilead to Topple GSK as the Top Player in the Anti-Infectives Drug Market in 2014

View Now